Alembic Pharmaceuticals Limited announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ivabradine Tablets, 5 mg and 7.5 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Corlanor Tablets, 5 mg and 7.5 mg, of Amgen Inc. (Amgen).
- Read more about Alembic Pharmaceuticals receives USFDA Tentative approval for Ivabradine Tablets
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/alembic-pharmaceuticals-receives-usfda-tentative-approval-for-ivabradine-tablets
No comments:
Post a Comment